Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.

ABSTRACT:

Importance

Use of next-generation sequencing (NGS) to identify clinically actionable genomic targets has been incorporated into routine clinical practice in the management of advanced solid tumors; however, the clinical utility of this testing remains uncertain.

Objective

To determine which patients derived the greatest degree of clinical benefit from NGS profiling.

Design, setting, and participants

Patients in this cohort study underwent fresh tumor biopsy and blood sample collection for genomic profiling of paired tumor and normal DNA (whole-exome or targeted-exome capture with analysis of 1700 genes) and tumor transcriptome (RNA) sequencing. Somatic and germline genomic alterations were annotated and classified according to degree of clinical actionability. Results

SUBMITTER: Cobain EF 

PROVIDER: S-EPMC7907987 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature